Slough's new chief executive, Ian Coull, has asked UBS to draw up a range of options for unlocking the value in its American assets. These include a sale, wholesale demerger, retaining a stake in a new company or a tax-efficient property investment trust.
The aim is to streamline Slough into a specialist development company better equipped to generate improved returns on capital than it can from pure property investment.
Slough has built a profitable business in the southern California property market with the development of the biotechnology parks. They have attracted tenants like Pfizer which now occupies 25% of the property in the portfolio and this has boosted the investment value of the estate.
Other areas where Slough believes there is a need for specialist developments included Washington, Boston, Philadelphia and Baltimore.
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more inforrmation visit Asset & Logo Licensing.
